ClinicalTrials.gg
Not yet recruitingNCT07411170WARM-HFUpdated Jun 29, 2026

Wearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial

An interventional study of Wearable Device-Assisted Intervention in HFrEF - Heart Failure With Reduced Ejection Fraction and AF - Atrial Fibrillation, sponsored by Beijing Anzhen Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
13th of 24
400 · median 410
Started
2026
with 10 others
No phase
21 of 36
15 open now
Primary completion
2026-12
later than 5 of 25 live
Registered
27th of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 13th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 27th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

Patients with acute decompensated heart failure (HF) have a significantly high risk of death and HF re-hospitalization during the vulnerable phase post discharge. Therefore, early post-discharge management is crucial, and the cornerstone of HF treatment-particularly for HF with reduced ejection fraction (HFrEF)-is guideline-directed medical therapy (GDMT), a comprehensive pharmacotherapeutic strategy supported by robust clinical evidence. Timely titration of GDMT, especially within the first few weeks after discharge, has been shown to improve clinical outcomes, reduce readmissions, and enhance long-term prognosis. However, ensuring optimal follow-up and therapeutic adjustments remains a major challenge in real-world practice. Atrial fibrillation (AF) is a common comorbidity in patients with HF, especially in those with severe HF. The presence of AF significantly complicates the clinical course and worsens the prognosis of HF.

Advances in wearable technology have made continuous, non-invasive monitoring of vital signs, arrhythmia burden, and physical status increasingly feasible. Devices such as smartwatches and ECG belts can provide real-time physiological data, offering new opportunities for remote and proactive disease management. Despite the growing availability of such data, the complex interplay between AF and HF demands highly personalized management. Currently, there is a lack of high-quality clinical evidence on how to effectively integrate wearable device data into personalized strategies for this specific patient population.

This is an open-label, multi-center, endpoint-blinded, parallel-group randomized clinical trial supported by the American Heart Association. The primary objective is to determine whether wearable device-assisted digital consultations can optimize GDMT in patients with AF complicated by acute decompensated HF. The study plans to enroll 400 participants, who will be randomly assigned to either a wearable device-assisted intervention group or a conventional treatment control group. The primary endpoint is the change in HF GDMT score 3 months after randomization.

Apple Inc. provided funding, devices, and technical support for this study. Apple was not a sponsor of the trial and was not involved in its execution, data analysis, interpretation, or manuscript preparation.

03

Conditions studied

  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • AF - Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Subjects diagnosed with acute decompensated heart failure (ADHF) :1)Heart failure with reduced (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40%;2) (NYHA) functional class II-IV;3)NT-proBNP > 2500 pg/mL or BNP > 600 pg/mL
  3. Atrial fibrillation (AF) diagnosed during hospitalization (documented AF episode lasting > 30 seconds on [ECG] within the past 12 months)

Exclusion criteria

Exclusion Criteria:

  1. Intolerance to heart failure pharmacotherapy
  2. Severe anemia, uncorrected thyroid disease
  3. ST-segment elevation myocardial infarction (STEMI) within 3 months
  4. Known complex congenital/secondary heart disease; infiltrative cardiomyopathy (e.g., cardiac amyloidosis, sarcoidosis, lymphoma, or endomyocardial fibrosis); myocarditis; constrictive pericarditis; cardiac tamponade; hypertrophic cardiomyopathy; stress cardiomyopathy (Takotsubo cardiomyopathy); or uncorrected primary valvular heart disease requiring surgical intervention.
  5. Previous or planned major cardiac surgery or mechanical circulatory support within 6 months, including coronary artery bypass grafting, cardiac valve repair or replacement, ventricular assist device or mechanical circulatory support device implantation, and heart transplantation.
  6. Current use of or planned implantation of a pacemaker.
  7. to wearing a smartwatch (e.g., limb disability or known allergy to rubber/metal materials)
  8. Inability to access the Internet or lack of proficiency in operating smart devices
  9. Pregnant or lactating women
  10. Organ transplantation within the past 12 months
  11. Expected survival time of less than 1 year for any reason
  12. Refusal to participate or inability to comply with follow-up requirements
  13. Deemed ineligible for participation in the study by the investigators
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Wearable Device-Assisted Intervention Group

    Other: Wearable Device-Assisted Intervention

  • No intervention
    Conventional Treatment Control Group

Interventions

  • OtherWearable Device-Assisted Intervention

    This intervention comprises two core components: (A) A data collecting system via smartwatch and ECG belt; and (B) A decision-support algorithms for risk stratification and medication dose adjustment based on real-time data. Participants will be instructed to wear both the Apple Watch and ECG belt for a minimum of 12-18 hours per day to monitor parameters, such as heart rhythm and respiratory rate. Participants will be prompted via the research APP to complete questionnaires for symptom, blood pressure, and body weight data. All collected data are automatically uploaded to a secure cloud-based platform. A centralized decision-support system analyzes the integrated information using a suite of predefined, multi-layered algorithms to identify patients requiring intervention. Patients will be stratified into three tiers based on integrated physiological metrics and symptom reports: Normal subgroup, Abnormal subgroup, and E-alarm subgroup.

06

What researchers measure

Primary outcomes

  1. Changes in Heart Failure Guideline-directed Medical Therapy (GDMT) Score

    High score favorable

    Time frame: 3 Months After Randomization

Secondary outcomes

  1. AF recurrence monitored by Apple Watch and ECG belt

    Time frame: 3 Months After Randomization

  2. AF burden monitored by ECG belt

    Time frame: 12 Months After Randomization

  3. Time to first HF hospitalization and/or cardiovascular death

    Time frame: 12 Months After Randomization

Other outcomes

  1. Change in NT-proBNP level

    Time frame: 3 Months After Randomization

  2. Change in 6-minute walk test (6MWT) result

    Time frame: 3 Months After Randomization

  3. Change in Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)

    High score favorable

    Time frame: 3 Months After Randomization

  4. Change in Minnesota Heart Failure Quality of Life Scale (MLHFQ)

    Low score favorable

    Time frame: 3 months from randomization

  5. Change in 5-level EuroQol 5-Dimension Questionnaire (EQ-5D-5L)

    Low score favorable

    Time frame: 3 months from randomization

  6. Time to first cardiovascular death

    Time frame: 12 Months After Randomization

  7. Time to first hospitalization for AF

    Time frame: 12 Months After Randomization

  8. Time to first readmission for AF or HF

    Time frame: 12 Months After Randomization

  9. Time to AF catheter ablation

    Time frame: 12 Months After Randomization

  10. HFimpEF (Heart Failure with Improved Ejection Fraction)

    Defined as a prior LVEF ≤40% that has increased to \>40%, with an absolute improvement of ≥10%

    Time frame: 12 Months After Randomization

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 4 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 13, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2026
CompletionEst.
Sep 2028
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07411170
Responsible party
Chang sheng Ma (Chief Physician, Beijing Anzhen Hospital) — Principal investigator
First posted
Feb 13, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Zhiyao Wei, MD., PhD.
Contact
weizhiyaoyx@163.com
010-15521192379

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion